Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Grace Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 12 | 11 | −1 |
| Shares | 410.6K | 389.5K | −21.1K (−5.1%) |
| Value | $189.6K | $204.2K | +$14.6K (+7.7%) |
New holders (2)
Institutions that held Grace Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 15,087 | $7.92K | 0.00% |
| Jane Street Group, LLC | 14,216 | $7.46K | 0.00% |
Sold out (3)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Virtu Financial LLC | 22,254 | $10.0K |
| UBS Group AG | 3,744 | $1.72K |
| JPMorgan Chase & Co | 1,250 | $1.00K |